一次情報の記録
決定級トップライン結果
AVTX-009 Phase 2 LOTUS試験（HS）：トップラインデータは2026年Q2に予定
Avaloは、AVTX-009のヒドラデニス・スポンティバにおけるPhase 2 LOTUS試験の登録を完了しました。トップライン結果は2026年Q2に予定されており、同資産の次の規制・臨床マイルストーンを確立します。
主要事実
出典の抜粋
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation,